2026-06-12 20:37:23
Latest Post
Royal Orchid Hotels Ltd strengthens Spiritual Tourism Portfolio with Launch of Regenta Devarayah Tirupati
JSW Energy Commissions 150 MW Tidong Hydro Project, taking Total Installed Capacity to ~13,900 MW
Hatton National Bank and Nucleus Software Celebrate Five Years of Partnership Driving Transaction Banking Transformation and Excellence, Powered by FinnAxia®
The Monarch Surveyors and Engineering Consultants Ltd receives order worth Rs. 5.25 crore
Jayant Infratech Ltd receives LoA worth Rs. 16.54 crores
Stock Report
Suven Life Sciences announces three poster presentations on Samelisant (SUVN-G3031), including global Phase-3, AWAKE Narcolepsy Study at SLEEP-2026
Posted On : 2026-06-12 17:02:12( TIMEZONE : IST )
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders today announced that it will present three posters at SLEEP-2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), LLC (APSS) being held at Baltimore, USA during June 14-17, 2026.
The APSS is a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society. The SLEEP meeting is the premier clinical and scientific meeting focused on sleep medicine, sleep and circadian research, and sleep health. SLEEP 2026 will feature more than 140 exhibits, 1,500 research abstract presentations, and 5,000 attendees, speakers, and exhibitors.
The presentations will showcase the clinical advancement of Samelisant (SUVN-G3031), including positive Phase 2 efficacy data in excessive daytime sleepiness (EDS), the rationale and design of a Phase 2 study for cataplexy in Type 1 narcolepsy, and the Phase 3 development strategy for Samelisant in patients with narcolepsy (AWAKE study).
Poster Presentations:
- Samelisant (SUVN-G3031) Demonstrates Significant Reduction in Excessive Daytime Sleepiness in Patients with Narcolepsy: Phase-2 Results (15 June, 2026; Poster # 374)
- Study Design and Rationale for a Phase-2 Study of Samelisant (SUVN-G3031) for the Treatment of Cataplexy in Patients with Type 1 Narcolepsy (15 June, 2026; Poster # 368)
- Phase-3 Clinical Development of Samelisant: Rationale and Study Design for Treating Excessive Daytime Sleepiness in Patients with Narcolepsy (16 June, 2026; Poster # 332)
Members of Suven scientific team scheduled several meetings at Suven Exhibit booth # 1034, with Phase-3 study Principle Investigators, KOLs and potential partnering companies.
Shares of Suven Life Sciences Limited was last trading in BSE at Rs. 263.25 as compared to the previous close of Rs. 268.70. The total number of shares traded during the day was 44579 in over 805 trades.
The stock hit an intraday high of Rs. 270.10 and intraday low of 260.15. The net turnover during the day was Rs. 11756005.00.
